Metastatic HER2 -amplified non-small-cell lung cancer treated with trastuzumab deruxtecan.
Karen M YunLyudmila BazhenovaPublished in: BMJ case reports (2023)
Human epidermal growth factor receptor 2 (HER2) alterations can occur as gene mutations, gene amplification or protein overexpression. DESTINY-Lung01 and DESTINY-Lung02 demonstrated the efficacy of trastuzumab deruxtecan in the subsequent line setting in patients with unresectable or metastatic HER2 -mutated non-small-cell lung cancer (NSCLC). Trastuzumab deruxtecan has not been studied in select patients with HER2 -amplified NSCLC. Here, we present the first reported case of metastatic HER2 -amplified NSCLC treated with trastuzumab deruxtecan with a durable response to therapy.
Keyphrases
- epidermal growth factor receptor
- advanced non small cell lung cancer
- small cell lung cancer
- tyrosine kinase
- squamous cell carcinoma
- endothelial cells
- brain metastases
- cell proliferation
- locally advanced
- genome wide
- gene expression
- copy number
- transcription factor
- metastatic breast cancer
- dna methylation
- induced pluripotent stem cells
- small molecule
- nucleic acid
- amino acid
- pluripotent stem cells